Gilead Sciences Inc. (GILD)

71.07
NASDAQ : Health Technology
Prev Close 71.52
Day Low/High 70.83 / 71.76
52 Wk Low/High 64.27 / 89.54
Avg Volume 7.07M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 92.99B
EPS 3.50
P/E Ratio 26.89
Div & Yield 2.28 (2.98%)

Latest News

Jim Cramer: Confounding Days

Jim Cramer: Confounding Days

The buyers of stocks on days like Tuesday make very little sense.

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation

Looking for stocks that could outperform during the current period of labor inflation? Try building a portfolio of these 50 stocks.

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

Here is a new index for all you traders out there to follow, compliments of TheStreet's founder Jim Cramer. Welcome to the GLUM Index.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer Of The Order Of Australia

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer Of The Order Of Australia

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his "distinguished service to medical...

Gilead Sciences Announces Leadership Changes In Corporate Development And Strategy

Gilead Sciences Announces Leadership Changes In Corporate Development And Strategy

Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead's corporate development, alliance management, competitive intelligence,...

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Kite Announces New Data Analyses For CAR T Therapy In Patients With Blood Cancers At The 2018 American Society Of Clinical Oncology Meeting

Kite Announces New Data Analyses For CAR T Therapy In Patients With Blood Cancers At The 2018 American Society Of Clinical Oncology Meeting

Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in...

Kite Announces Initial Results From A Phase 1 Study Of T Cell Receptor (TCR) Cell Therapy In HPV-16-Positive Solid Tumors

Kite Announces Initial Results From A Phase 1 Study Of T Cell Receptor (TCR) Cell Therapy In HPV-16-Positive Solid Tumors

Kite, a Gilead Company (Nasdaq: GILD), today announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting...

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Gilead Sciences To Present At The Jefferies 2018 Healthcare Conference On Wednesday, June 6

Gilead Sciences To Present At The Jefferies 2018 Healthcare Conference On Wednesday, June 6

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

FDA Publicly Shames Drug Companies to Encourage Generic Competition

FDA Publicly Shames Drug Companies to Encourage Generic Competition

Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.

Kite Announces New Worldwide Facilities And Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline

Kite Announces New Worldwide Facilities And Expanded Collaboration With National Cancer Institute To Support Cell Therapy Pipeline

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

Gilead Sciences Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Lam Research

The most recent short interest data has been released for the 04/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Harish Manwani Joins Gilead Sciences' Board Of Directors

Harish Manwani Joins Gilead Sciences' Board Of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M.

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Wednesday, May 16

Gilead Sciences To Present At The Bank Of America Merrill Lynch Healthcare Conference On Wednesday, May 16

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Gilead Sciences Announces Second Quarter 2018 Dividend

Gilead Sciences Announces Second Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces First Quarter 2018 Financial Results

Gilead Sciences Announces First Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2018.

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases

Gilead And Verily Announce Scientific Collaboration To Identify And Understand Immunological And Molecular Drivers Of Inflammatory Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily's Immunoscape platform to identify and better understand the immunological basis of three common and serious...

European CHMP Adopts Positive Opinion For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

European CHMP Adopts Positive Opinion For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization...

TheStreet Quant Rating: C (Hold)